Study of axatilimab with decitabine and venetoclax for TP53-mutated AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of drugs (axatilimab, decitabine, and venetoclax) for people with a specific type of acute myeloid leukemia (AML) that has a change in the TP53 gene. The goal is to see if this treatment can help when standard treatments haven't worked or for newly diagnosed patients with this genetic change.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have AML or MDS/AML with a TP53 gene mutation or deletion.
- You must either be untreated or in your first relapse or have not responded to initial treatment.
- You must be able to perform daily activities with minimal help (Karnofsky score of 60 or higher).
- You cannot have an active infection that is not under control, or a history of HIV, hepatitis B, or hepatitis C.
- Your kidneys and liver must be working well enough (certain blood test levels must be within range).
- You cannot have had a stem cell transplant within the last 3 months, or have certain heart or pancreas problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining a new drug called ATRN-119 with a cancer medicine called decitabine can help patients with acute myeloid leukemia (AML) or a related bone marrow condition called high-risk myelodysplastic syndrome (MDS), especially those whose cancer cells have changes in a gene called TP53. The trial is looking for patients who have not responded to or cannot tolerate standard treatments.
This trial tests a combination of three drugs (tagraxofusp, azacitidine, and venetoclax) for people newly diagnosed with a type of acute myeloid leukemia (AML) that has developed after treatment with certain prior drugs (hypomethylating agents). The goal is to see if this combination is safe and effective.
This trial tests a new combination of two drugs (bortezomib and CPX-351) for people newly diagnosed with a specific type of AML that has a TP53 gene change. The goal is to see if this combination is safe and works better than standard treatment.
This trial tests a treatment that combines a personalized vaccine made from your leukemia cells and your own immune cells (T cells) with standard chemotherapy drugs (decitabine and venetoclax). The goal is to help your immune system better fight the leukemia.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.